Barclays Maintains an 'Overweight' on Lam Research (LRCX); Adjusting Estimates Post Merger
Tweet
Share
E-mailGet Alerts LRCX Hot Sheet
Price: $332.36 -1.38%
Rating Summary:
33 Buy, 10 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
33 Buy, 10 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Barclays maintains an 'Overweight' on Lam Research (NASDAQ: LRCX) price target of $48.00.
Analyst, C.J. Muse, said, "...Big picture, we continue to see ongoing earnings power for the company of ~$4. As for the outlook for shares from here, we do view the continued share repurchasing plus likely market share wins at Intel (Nasdaq: INTC) as near-term positive catalysts, but do wonder if Lam continues to be viewed as a NAND play, suggesting NAND spending will need to recover in order for the shares to work."
Sees June Qtr revenues of approx. $791 million and Sept qtr at about $1.05 billion. Barclays cuts FY12 EPS from $2.14 to $2.08 and FY13 from $3.28 to $3.20.
For an analyst ratings summary and ratings history on Lam Research click here. For more ratings news on Lam Research click here.
Shares of Lam Research closed at $35.99 yesterday.
Analyst, C.J. Muse, said, "...Big picture, we continue to see ongoing earnings power for the company of ~$4. As for the outlook for shares from here, we do view the continued share repurchasing plus likely market share wins at Intel (Nasdaq: INTC) as near-term positive catalysts, but do wonder if Lam continues to be viewed as a NAND play, suggesting NAND spending will need to recover in order for the shares to work."
Sees June Qtr revenues of approx. $791 million and Sept qtr at about $1.05 billion. Barclays cuts FY12 EPS from $2.14 to $2.08 and FY13 from $3.28 to $3.20.
For an analyst ratings summary and ratings history on Lam Research click here. For more ratings news on Lam Research click here.
Shares of Lam Research closed at $35.99 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
- Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating
- Vivos Therapeutics posts 35% revenue gain but widens net loss
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS ViewRelated Entities
Barclays, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
